Humacyte, Inc. (NASDAQ:HUMA) Short Interest Up 24.3% in September

Humacyte, Inc. (NASDAQ:HUMA) was the target of a large increase in short interest during the month of September. As of September 15th, there was short interest totalling 14,010,000 shares, an increase of 24.3% from the August 31st total of 11,270,000 shares. Based on an average trading volume of 3,270,000 shares, the days-to-cover ratio is currently 4.3 days. Approximately 15.0% of the company’s stock are sold short.

Humacyte Stock Performance

NASDAQ HUMA opened at $5.60 on Monday. The stock has a market capitalization of $666.87 million, a price-to-earnings ratio of -5.60 and a beta of 1.47. The business’s 50 day moving average is $6.60 and its two-hundred day moving average is $5.69. Humacyte has a 12-month low of $1.96 and a 12-month high of $9.97. The company has a current ratio of 5.41, a quick ratio of 5.41 and a debt-to-equity ratio of 0.61.

Humacyte (NASDAQ:HUMA) last announced its quarterly earnings data on Tuesday, August 13th. The company reported ($0.27) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.04). Research analysts expect that Humacyte will post -1.09 EPS for the current year.

Wall Street Analysts Forecast Growth

HUMA has been the topic of a number of research reports. Benchmark restated a “buy” rating and set a $15.00 price target on shares of Humacyte in a research note on Thursday, September 5th. Cantor Fitzgerald restated an “overweight” rating and set a $13.00 target price on shares of Humacyte in a research report on Friday, September 20th. BTIG Research upped their price target on shares of Humacyte from $8.00 to $11.00 and gave the company a “buy” rating in a research report on Monday, July 15th. Finally, EF Hutton Acquisition Co. I upgraded shares of Humacyte to a “strong-buy” rating in a research note on Monday, September 9th. One analyst has rated the stock with a hold rating, four have assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Buy” and an average price target of $9.80.

Insider Activity

In other Humacyte news, Director Brady W. Dougan sold 352,112 shares of the stock in a transaction that occurred on Thursday, August 29th. The shares were sold at an average price of $6.35, for a total value of $2,235,911.20. Following the transaction, the director now directly owns 3,677,262 shares in the company, valued at $23,350,613.70. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other Humacyte news, CEO Laura E. Niklason sold 157,704 shares of the company’s stock in a transaction on Monday, September 9th. The shares were sold at an average price of $5.42, for a total value of $854,755.68. Following the completion of the transaction, the chief executive officer now owns 3,519,558 shares in the company, valued at $19,076,004.36. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Brady W. Dougan sold 352,112 shares of Humacyte stock in a transaction dated Thursday, August 29th. The stock was sold at an average price of $6.35, for a total value of $2,235,911.20. Following the sale, the director now owns 3,677,262 shares in the company, valued at approximately $23,350,613.70. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 1,084,153 shares of company stock worth $6,869,996. 23.10% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Humacyte

Several hedge funds and other institutional investors have recently bought and sold shares of the company. nVerses Capital LLC purchased a new stake in shares of Humacyte in the second quarter valued at about $28,000. China Universal Asset Management Co. Ltd. lifted its stake in Humacyte by 65.9% in the 1st quarter. China Universal Asset Management Co. Ltd. now owns 19,883 shares of the company’s stock valued at $62,000 after buying an additional 7,897 shares in the last quarter. Hartline Investment Corp acquired a new stake in Humacyte during the 1st quarter valued at $70,000. Principal Financial Group Inc. purchased a new position in Humacyte during the second quarter worth $83,000. Finally, Profund Advisors LLC acquired a new position in shares of Humacyte in the second quarter worth $97,000. 44.71% of the stock is owned by institutional investors and hedge funds.

About Humacyte

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.